Daniel Patrick O'day
CEO, Chair at Gilead Sciences, Inc. (GILD)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $52.4M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Oct 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 12,000 | $147.72 | $1.8M | -2.1% |
| Oct 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 3,000 | $148.63 | $446K | -2.7% |
| Sep 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 1,600 | $147.51 | $236K | -2.0% |
| Sep 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 7,992 | $148.36 | $1.2M | -2.5% |
| Sep 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 5,408 | $149.38 | $808K | -3.2% |
| Aug 4SEC | GILDGilead Sciences, Inc. | Sell Plan | 6,700 | $129.66 | $869K | +11.5% |
| Aug 4SEC | GILDGilead Sciences, Inc. | Sell Plan | 7,700 | $130.80 | $1.0M | +10.6% |
| Aug 4SEC | GILDGilead Sciences, Inc. | Sell Plan | 600 | $131.34 | $79K | +10.1% |
| Jul 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 11,900 | $126.09 | $1.5M | +14.7% |
| Jul 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 3,100 | $127.08 | $394K | +13.8% |
| Jun 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 10,900 | $131.10 | $1.4M | +10.3% |
| Jun 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 3,062 | $132.22 | $405K | +9.4% |
| Jun 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 1,038 | $132.97 | $138K | +8.8% |
| Apr 29SEC | GILDGilead Sciences, Inc. | Sell Plan | 6,950 | $128.79 | $895K | +12.3% |
| Apr 29SEC | GILDGilead Sciences, Inc. | Sell Plan | 3,050 | $130.01 | $397K | +11.2% |
| Mar 30SEC | GILDGilead Sciences, Inc. | Sell Plan | 10,000 | $136.82 | $1.4M | +5.7% |
| Mar 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 3,481 | $144.04 | $501K | +0.4% |
| Mar 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 6,419 | $145.18 | $932K | -0.4% |
| Mar 2SEC | GILDGilead Sciences, Inc. | Sell Plan | 100 | $145.71 | $15K | -0.7% |
| Feb 6SEC | GILDGilead Sciences, Inc. | Sell Plan | 115,640 | $150.00 | $17.3M | -3.6% |
| Jan 29SEC | GILDGilead Sciences, Inc. | Sell Plan | 5,032 | $139.54 | $702K | +3.6% |
| Jan 29SEC | GILDGilead Sciences, Inc. | Sell Plan | 4,968 | $140.24 | $697K | +3.1% |
| Jan 26SEC | GILDGilead Sciences, Inc. | Sell Plan | 115,640 | $135.00 | $15.6M | +7.1% |
| Dec 30SEC | GILDGilead Sciences, Inc. | Sell Plan | 10,000 | $124.83 | $1.2M | +15.9% |
| Dec 1SEC | GILDGilead Sciences, Inc. | Sell Plan | 3,212 | $125.91 | $404K | +14.9% |
| Dec 1SEC | GILDGilead Sciences, Inc. | Sell Plan | 6,788 | $126.84 | $861K | +14.0% |
| Oct 29SEC | GILDGilead Sciences, Inc. | Sell Plan | 7,978 | $119.54 | $954K | +21.0% |
| Oct 29SEC | GILDGilead Sciences, Inc. | Sell Plan | 2,022 | $118.82 | $240K | +21.7% |
- Sell
CEO, Chair Daniel Patrick O'day sold $1.8M of GILD at $147.72 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, Chair Daniel Patrick O'day sold $446K of GILD at $148.63 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, Chair Daniel Patrick O'day sold $236K of GILD at $147.51 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, Chair Daniel Patrick O'day sold $1.2M of GILD at $148.36 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, Chair Daniel Patrick O'day sold $808K of GILD at $149.38 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, Chair Daniel Patrick O'day sold $869K of GILD at $129.66 — pre-scheduled 10b5-1 plan sale.